Amylin (AMLN) Shareholders Want Change - NOW!
To make matters worse for Amylin management, Eastbourne acknowledged Icahn's slate, but said it does not believe that these separate efforts to bring change to Amylin are in competition with each other. In other words, vote for ours or vote for theirs, either way we want change - NOW!
Our own Lon Juricic commented on the Icahn news for Barrons.com tonight. Lon said that Ichan's involvement with Amylin looks poised to be a repeat of his success at ImClone, which was sold to Eli Lilly (NYSE: LLY) for $70 per share, after a bidding war with Bristol-Myers Squibb (NYSE: BMY). Lon told Barron's, "Icahn kept building his position and eventually became chairman of the board, where he could push his agenda and positioned ImClone for a graceful sale... I could see this as the same situation playing out"
Ultimately, the shareholder activism at Amylin should be good news for investors.
Labels: AMLN, Amylin Pharmaceuticals, Carl Icahn, Eastbourne Capital
11 Comments:
Hi. This is an informative post
forex guides
Hi. This is an informative post
forex guides
here is something tells about the shareholders.
Thanks for sharing your precious comprehension with me.
It looks quite interesting on here and there seems to be loads of things up for discussion.
nice post I like your site very well and continue to do so. I have brokemark your site.
You guys are hilarious--a pleasure to read every day.
I could see this as the same situation playing out"
Ultimately, the shareholder activism at Amylin should be good news for investors.
I could see this as the same situation playing out"
thanks for share blog,its very informative.
change for the new rules and regulations for the company's success :)
Post a Comment
<< Home